

# Rachel G Woodford Bmed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6926868/publications.pdf>

Version: 2024-02-01

7  
papers

44  
citations

1937685

4  
h-index

1872680

6  
g-index

7  
all docs

7  
docs citations

7  
times ranked

37  
citing authors

#	ARTICLE	IF	CITATIONS
1	The validity of progression-free survival 2 as a surrogate trial end point for overall survival. <i>Cancer</i> , 2022, 128, 1449-1457.	4.1	15
2	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1793-1799.	2.4	6
3	Immunotherapy-related gastritis: Two case reports and literature review. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110285.	1.3	8
4	Combination chemotherapy with NAB <sup>®</sup> paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP <sup>®</sup> CAPABIL Pilot Study). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	1.1	5
5	Disseminated intravascular coagulation complicating diagnosis of ROS1 mutant non-small cell lung cancer: A case report and literature review. <i>Thoracic Cancer</i> , 2021, 12, 2400-2403.	1.9	6
6	Revisiting intrathecal neurolysis for refractory cancer pain: A case series. <i>Progress in Palliative Care</i> , 2020, 28, 366-368.	1.2	0
7	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	2.4	4